Evidence map›Paper›PMID 28203618›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2017

Negative commercial screening test for paraneoplastic antibodies in a case of opsoclonus.

Nicolas Vandenbussche, Catherine Cassiman, Maarten Schrooten, Benjamin Gille, Xavier Bossuyt, Thierry Vincent, Philip Van Damme, Koen Poesen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nicolas VandenbusscheDepartment of Neurology (N.V., M.S., P.V.D.), Department of Ophthalmology (C.C.), and Laboratory Medicine (X.B., K.P.), University Hospital Leuven; Department of Microbiology and Immunology (X.B.), Experimental Laboratory Immunology, Leuven, Belgium; Department of Immunology (T.V.), St Eloi Hospital, Montpellier University, France; Department of Neurosciences (P.V.D.), Laboratory for Neurobiology; Vesalius Research Center (P.V.D.), Flemish Institute for Biotechnology (VIB); and Department of Neurosciences (B.G., K.P.), Laboratory for Molecular Neurobiomarker Research, Leuven, Belgium.
Catherine CassimanDepartment of Neurology (N.V., M.S., P.V.D.), Department of Ophthalmology (C.C.), and Laboratory Medicine (X.B., K.P.), University Hospital Leuven; Department of Microbiology and Immunology (X.B.), Experimental Laboratory Immunology, Leuven, Belgium; Department of Immunology (T.V.), St Eloi Hospital, Montpellier University, France; Department of Neurosciences (P.V.D.), Laboratory for Neurobiology; Vesalius Research Center (P.V.D.), Flemish Institute for Biotechnology (VIB); and Department of Neurosciences (B.G., K.P.), Laboratory for Molecular Neurobiomarker Research, Leuven, Belgium.
Maarten SchrootenDepartment of Neurology (N.V., M.S., P.V.D.), Department of Ophthalmology (C.C.), and Laboratory Medicine (X.B., K.P.), University Hospital Leuven; Department of Microbiology and Immunology (X.B.), Experimental Laboratory Immunology, Leuven, Belgium; Department of Immunology (T.V.), St Eloi Hospital, Montpellier University, France; Department of Neurosciences (P.V.D.), Laboratory for Neurobiology; Vesalius Research Center (P.V.D.), Flemish Institute for Biotechnology (VIB); and Department of Neurosciences (B.G., K.P.), Laboratory for Molecular Neurobiomarker Research, Leuven, Belgium.
Benjamin GilleDepartment of Neurology (N.V., M.S., P.V.D.), Department of Ophthalmology (C.C.), and Laboratory Medicine (X.B., K.P.), University Hospital Leuven; Department of Microbiology and Immunology (X.B.), Experimental Laboratory Immunology, Leuven, Belgium; Department of Immunology (T.V.), St Eloi Hospital, Montpellier University, France; Department of Neurosciences (P.V.D.), Laboratory for Neurobiology; Vesalius Research Center (P.V.D.), Flemish Institute for Biotechnology (VIB); and Department of Neurosciences (B.G., K.P.), Laboratory for Molecular Neurobiomarker Research, Leuven, Belgium.
Xavier BossuytDepartment of Neurology (N.V., M.S., P.V.D.), Department of Ophthalmology (C.C.), and Laboratory Medicine (X.B., K.P.), University Hospital Leuven; Department of Microbiology and Immunology (X.B.), Experimental Laboratory Immunology, Leuven, Belgium; Department of Immunology (T.V.), St Eloi Hospital, Montpellier University, France; Department of Neurosciences (P.V.D.), Laboratory for Neurobiology; Vesalius Research Center (P.V.D.), Flemish Institute for Biotechnology (VIB); and Department of Neurosciences (B.G., K.P.), Laboratory for Molecular Neurobiomarker Research, Leuven, Belgium.
Thierry VincentDepartment of Neurology (N.V., M.S., P.V.D.), Department of Ophthalmology (C.C.), and Laboratory Medicine (X.B., K.P.), University Hospital Leuven; Department of Microbiology and Immunology (X.B.), Experimental Laboratory Immunology, Leuven, Belgium; Department of Immunology (T.V.), St Eloi Hospital, Montpellier University, France; Department of Neurosciences (P.V.D.), Laboratory for Neurobiology; Vesalius Research Center (P.V.D.), Flemish Institute for Biotechnology (VIB); and Department of Neurosciences (B.G., K.P.), Laboratory for Molecular Neurobiomarker Research, Leuven, Belgium.
Philip Van DammeDepartment of Neurology (N.V., M.S., P.V.D.), Department of Ophthalmology (C.C.), and Laboratory Medicine (X.B., K.P.), University Hospital Leuven; Department of Microbiology and Immunology (X.B.), Experimental Laboratory Immunology, Leuven, Belgium; Department of Immunology (T.V.), St Eloi Hospital, Montpellier University, France; Department of Neurosciences (P.V.D.), Laboratory for Neurobiology; Vesalius Research Center (P.V.D.), Flemish Institute for Biotechnology (VIB); and Department of Neurosciences (B.G., K.P.), Laboratory for Molecular Neurobiomarker Research, Leuven, Belgium.
Koen PoesenDepartment of Neurology (N.V., M.S., P.V.D.), Department of Ophthalmology (C.C.), and Laboratory Medicine (X.B., K.P.), University Hospital Leuven; Department of Microbiology and Immunology (X.B.), Experimental Laboratory Immunology, Leuven, Belgium; Department of Immunology (T.V.), St Eloi Hospital, Montpellier University, France; Department of Neurosciences (P.V.D.), Laboratory for Neurobiology; Vesalius Research Center (P.V.D.), Flemish Institute for Biotechnology (VIB); and Department of Neurosciences (B.G., K.P.), Laboratory for Molecular Neurobiomarker Research, Leuven, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID28203618
PMCPMC5292927

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.